Kyverna Therapeutics, Inc. - 8-K Filing
Kyverna Therapeutics reported $236.4 million in cash as of March 31, 2026, with a net loss of $39.7 million for the quarter (or $0.66 per share). The company initiated a rolling BLA submission for miv-cel in stiff person syndrome following FDA alignment and presented positive one-year follow-up data showing durable efficacy without chronic immunotherapies. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $KYTX